Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with...
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan
About this item
Full title
Author / Creator
Publisher
Athens: D.A. Spandidos
Journal title
Language
English
Formats
Publication information
Publisher
Athens: D.A. Spandidos
Subjects
More information
Scope and Contents
Contents
Poly(ADP-ribose) polymerase inhibitors (PARPi) are currently evaluated in clinical trials in combination with topoisomerase I (Top1) inhibitors against a variety of cancers, including colon carcinoma. Since the mismatch repair component MLH1 is defective in 10-15% of colorectal cancers we have investigated whether MLH1 affects response to the Top1...
Alternative Titles
Full title
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1932334512
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1932334512
Other Identifiers
ISSN
1019-6439
E-ISSN
1791-2423
DOI
10.3892/ijo.2013.1932
